Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a single breast MRI at 45 catch cancer earlier?

NCT ID NCT07878377

NEW Diagnosis Sponsor: Radboud University Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Oct 16, 2026 · Last updated Oct 16, 2026

Summary

Researchers in the Netherlands are studying whether a one-time breast MRI scan at age 45 can detect breast cancer early in women who are not yet in routine screening. About 2,600 women will receive a high-resolution MRI and complete questionnaires about their reasons for joining, their cancer-related worry, and their experience. The study also tracks the cost per cancer found and follows a subset of women one year later to see how screening affects their health beliefs.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a one-time breast MRI screening scan
What this could lead to
If it works, this could point toward a new way to spot breast cancer earlier in women around age 45, when standard mammograms are not routine. It could also help health systems weigh the costs and benefits of MRI-based screening.
What could go wrong
MRI can flag harmless findings that lead to extra tests and anxiety, called false positives. A single scan at one age may miss cancers that develop later, and the study does not yet show whether finding cancer earlier saves lives.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 2,628 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2027

An estimate. Start dates often move.

Expected to finish

Dec 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

45 to 45 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women aged 45 years at the time of enrollment * Resident in the Netherlands * Able and willing to provide informed consent Exclusion Criteria: * Current pregnancy or breastfeeding * Known renal disease with estimated glomerular filtration rate (eGFR) \< 60 * Severe claustrophobia * Contraindication for breast MRI (e.g., pacemakers or neurostimulators) * Contraindication for intravenous contrast administration (e.g., previous allergic reaction to contrast agent) * Lifetime breast cancer risk ≥ 20% according to CanRisk evaluation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer Breast cancer detection Screening strategy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.